Discover

RARE
Ultragenyx Pharmaceutical Inc.
26.81
1 x 26.81
3 x 26.83
bid
ask
+
0.01
0.03%
01:41 PM
timesize
Ytd16.55%
1y-2.13%
26.42
day range
27.59
18.29
52 week range
39.89
Open27.13Prev Close26.80Low26.42High27.59Mkt Cap2.64B
Vol742.90KAvg Vol2.24MEPS-5.84P/E-4.59Forward P/E8.12
Beta0.35Short Ratio4.24Inst. Own110.14%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0450-d Avg27.69200-d Avg26.781yr Est52.84
Income Statement
Total Revenue214.00M
Revenues (USD)214.00M
Cost of Revenue34.00M
Gross Profit180.00M
Operating Expenses255.00M
Research and Development Expense167.00M
Selling, General and Administrative Expense88.00M
Operating Income-75.00M
Income Tax Expense1000.00K
Net Income-92.00M
Net Income Common Stock-92.00M
Net Income Common Stock (USD)-92.00M
Consolidated Income-92.00M
Earnings per Basic Share-0.90
Earnings per Basic Share (USD)-0.90
Earnings per Diluted Share-0.90
Earning Before Interest & Taxes (EBIT)-91.00M
Earning Before Interest & Taxes (USD)-91.00M
Weighted Average Shares101.90M
Weighted Average Shares Diluted101.90M
Balance Sheet
Cash and Equivalents125.00M
Cash and Equivalents (USD)125.00M
Investments311.00M
Investments Current167.00M
Investments Non-Current144.00M
Trade and Non-Trade Receivables200.00M
Current Assets606.00M
Property, Plant & Equipment Net235.00M
Total Assets1.26B
Debt Current76.00M
Total Debt1.20B
Current Liabilities351.00M
Debt Non-Current1.13B
Total Liabilities1.55B
Accumulated Retained Earnings (Deficit)-4.81B
Shareholders Equity-298.00M
Shareholders Equity (USD)-298.00M
Assets Non-Current658.00M
Total Debt (USD)1.20B
Goodwill and Intangible Assets216.00M
Inventory59.00M
Liabilities Non-Current1.20B
Trade and Non-Trade Payables39.00M
Tax Liabilities30.00M
Cash Flow
Depreciation, Amortization & Accretion8.00M
Net Cash Flow / Change in Cash & Cash Equivalents-49.00M
Capital Expenditure-1000.00K
Net Cash Flow from Investing44.00M
Net Cash Flow - Investment Acquisitions and Disposals48.00M
Net Cash Flow from Operations-97.00M
Effect of Exchange Rate Changes on Cash 1000.00K
Share Based Compensation34.00M